when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Pulmonology · news · pharmadog

← back to Pulmonology

News · Pulmonology

515 stories

May 15, 26STAT+: Up and down the ladder: The latest comings and goingsstat

May 14, 26MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategiesonclive

May 14, 26Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Lossonclive

May 13, 26Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?stat

May 13, 26UCSF Receives Major Gift to Advance Research and Modernizationonclive

May 13, 26How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCOonclive

May 12, 26Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanomaonclive

May 12, 26Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Riskonclive

May 12, 26EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCsonclive

May 12, 26Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Canceronclive

May 12, 26EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapyonclive

May 12, 26Sequencing ADCs in Endometrial Canceronclive

May 11, 26Dr Silbermann on Clinical Trial Design Considerations in Multiple Myelomaonclive

May 11, 26MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumorsonclive

May 11, 26Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialbiopharma dive

May 11, 26Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTonclive

May 11, 26Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selectiononclive

May 11, 26Expanding ctDNA Applications to RCC and Germ Cell Tumorsonclive

May 11, 26RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practiceonclive

May 11, 26ctDNA in Metastatic Urothelial Carcinomaonclive

May 11, 26Institutional Perspectives on Treatment Thresholds in PLGGonclive

May 11, 26Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groupsonclive

May 11, 26Animal skin disease confirmed in clusters of European men who have sex with menstat

May 10, 26Five Under 5: Top Oncology Videos for the Week of 5/3onclive

May 9, 26ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Interventiononclive

May 9, 26Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national newsstat

May 9, 26The OncFive: Top Oncology Articles for the Week of 5/3onclive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDonclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

← prevpage 15 of 18next →